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Abstract
As a novel concept of responding to disease epidemics, Fangcang shelter hospitals were
deployed to expand the health system’s capacity and provide medical services for non-
severe COVID-19 patients during the outbreak in Wuhan. To give insights on patient man-
agement within Fangcang hospitals, we conducted a retrospective analysis to: 1) describe
the characteristics of the patients admitted to Fangcang hospitals and 2) explore risk factors
for longer length of stay (LOS). We enrolled 136 confirmed COVID-19 patients, including
asymptomatic patients and those with mild symptoms, who were hospitalized in theWuti
Fangcang Hospital. 58 patients completed the treatment and discharged before 1 March
2020. After describing patients’ demographic and clinical characteristics, exposure history,
treatment received and time course of the disease, we conducted linear regression analysis
to identify factors influencing LOS. We found that patients having fever before admission
were hospitalized 3.5 days (95%CI 1.39 to 5.63, p = 0.002) longer than those without fever
and that patients having bilateral pneumonia were hospitalized 3.4 days (95%CI 0.49 to
6.25, p = 0.023) longer than those with normal CT scan results. We also found weak evi-
dence suggesting that patients with diabetes were hospitalized 3.2 days longer than those
without diabetes (95%CI -0.2 to 6.56, p = 0.065). However, we observed no significant differ-
ences in LOS between symptomatic and asymptomatic patients and between patients who
received treatment and those without treatment. Longer duration of hospitalization among
non-severe COVID-19 patients is associated with having fever, bilateral pneumonia on CT
scan and diabetes. However, being asymptomatic and using supportive medications at the
early stage of infection do not have significant influences on LOS. Our study is a single-cen-
tered study with relatively small sample size. The findings provide evidence for predicting
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Introduction
COVID-19, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
has rapidly become a global pandemic since it was first reported in December 2020. As of 8
July 2020, over 11 million cases and 535,759 deaths have been reported worldwide [1]. The
COVID-19 pandemic not only overburdens the intensive care units with influx of critically ill
patients, but also challenges the health systems’ capacity to respond to the needs of non-severe
patients who require necessary examinations and treatment.
To accommodate for the surge of COVID-19 patients in Wuhan—the former epicenter of
China–in January and February 2020, the Chinese government successfully expanded the
health system’s capacity in a short time by implementing a patient triage scheme and adopting
a novel concept of responding to public health emergency–Fangcang hospitals. Converted
from stadium or exhibition centers, Fangcang hospitals are temporary hospitals providing
medical care during large-scale emergencies, such as earthquakes or floods. According to the
COVID-19 diagnosis and treatment guideline (6th edition) in China, confirmed COVID-19
cases were categorized into four groups—minor, moderate, severe and critical—based on clini-
cal manifestations [2]. Patients with minor and moderate symptoms were admitted to Fang-
cang hospitals once they were diagnosed with COVID-19. Additionally, since frontline
doctors reported cases of asymptomatic and presymptomatic transmission, asymptomatic
patients identified from quarantine sites or screening of close contacts of confirmed cases were
also admitted to Fangcang hospitals [3–5]. If patients’ conditions deteriorated, they would be
transferred to one of the designated tertiary hospitals where critical care was available. In a
published article, the authors highlighted the functions of Fangcang hospitals and emphasized
their critical roles in the national responses to the COVID-19 epidemics in China [6]. How-
ever, studies giving more insights on patient management within Fangcang hospitals and the
characteristics of patients in these hospitals are scarce [7].
Furthermore, although strict social confinement measures seem to be effective in reducing
case incidence and mortality in the first wave [8–11], as many countries have already lifted
lockdown or are in the process of doing so, there is a great risk of a larger second wave of
COVID-19 happening in the following months, which poses a major threat to the already
taxed health systems in many countries [12, 13]. Therefore, early preparation to ramp up the
health system capacity is crucial in the event of the second wave [13, 14].
Understanding how long COVID-19 patients require healthcare in hospitals is important
for predicting hospital bed demand and planning resource allocation, particularly in resource
constraint settings. Many existing studies suggest that patients’ characteristics that influence dis-
ease severity are likely to influence the length of stay (LOS) in hospitals [15–19], but no conclu-
sion is drawn because LOS is often reported as one of the secondary outcomes without being
further analyzed [20]. We only found three studies that investigated the risk factors influencing
LOS among COVID-19 patients [21–23]. In these studies, prolonged hospitalization of
COVID-19 patients was found to be associated with being female, having fever, having chronic
liver or kidney disease on admission, higher creatine level, lymphopenia, and bilateral pneumo-
nia on CT scan [21, 22]. However, no consensus on particular risk factors has been reached.
Therefore, the purpose of this study is to: 1) describe the characteristics of the non-severe
patients who were hospitalized in Fangcang hospitals; 2) explore risk factors for longer LOS
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As one of the 16 Fangcang hospitals operated during the COVID-19 outbreak inWuhan, the
Qiaokou district Wuti Fangcang Hospital (Qiaokou Fangcang Hospital) started to receive
patients on 11 February 2020. A medical team from Shanxi province was responsible for pro-
viding health services at the Qiaokou Fangcang Hospital, with assistance from the local gov-
ernment and a local tertiary hospital. Patients who were admitted to Fangcang hospitals met
the following criteria: 1) tested positive in RT-PCR test for SARS-CoV-2; 2) having self-care
ability; 3) having mild or moderate symptoms; 4) no severe comorbidities (such as heart fail-
ure, renal failure) or mental disorders; 5) tested negative in an influenza virus RT-PCR test.
Asymptomatic patients identified from quarantine sites or screening of the close contacts of
confirmed cases were also admitted to Fangcang hospitals for isolation.
Apart from its function of isolating and triaging COVID-19 patients, the Qiaokou Fang-
cang Hospital provided the following essential services. First, it served as a shelter that pro-
vided essential living necessities to patients, such as accommodation, food, sanitation services
and social engagement. Second, patients’ conditions were monitored by the healthcare provid-
ers, as body temperature, blood pressure and oxygen saturation were checked multiple times
daily. Mobile CT scanner and blood testing lab were available onsite for more specialized
examinations. Third, basic medical care, including oral and intravenous medications, oxygen
supplementation and mental health counseling, were available and provided to those patients
in need.
Study participants
Patients meeting the following criteria were discharged: 1) having a normal body temperature
for three consecutive days; 2) no significant respiratory symptoms; 3) significant improvement
of pneumonia on chest CT scan; 4) two consecutive negative results for RT-PCR test 24 hours
apart.
On the contrary, if patients’ condition deteriorated and met one of the following criteria,
the patients were transferred to a designated hospital for further treatment: 1) respiratory
rate� 30/minute; 2) blood oxygen saturation�93% on room air; 3) oxygenation index� 300
mmHg; 4) body temperature� 38.5 Celsius degree for two consecutive days after treatment;
5) comorbidities deteriorated severely during hospitalization; 6) other emergency medical
reasons.
Fig 1 shows the triage flow at the Qiaokou Fangcang Hospital. A total of 330 confirmed
COVID-19 patients were admitted to the Qiaokou Fangcang Hospital between 11 February
and 1 March 2020. To improve the efficiency of patient management, an electronic medical
records system was developed onsite. After the launch of the electronic system, health informa-
tion of 136 patients who were admitted to the Qiaokou Fangcang Hospital was updated to and
stored in the system. Among the 136 patients with complete medical records, while nine
patients were transferred to a designated hospital due to disease deterioration, 58 patients met
the criteria and were discharged before 1 March 2020. Because the Qiaokou Fangcang hospital
was closed on 1 March 2020, patients with mild symptoms who did not meet the discharge cri-
teria were transferred to another hospital for continuing isolation and treatment. In this study,
we only included the 58 patients who recovered and were discharged before the closure of the
Qiaokou Fangcang hospital.
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Data collection
Patients’ health information was collected between 25 February and 1 March 2020 by the med-
ical team from the Shanxi Bethune Hospital and stored in the electronic medical records sys-
tem. In addition to the date of hospital admission and discharge, the following data was
extracted from the electronic system by two researchers (LP and XLP): 1) patients’ demo-
graphic information (age and gender); 2) clinical information, including comorbidities, smok-
ing status, levels of white blood cell (WBC), lymphocyte and c-reactive protein (CRP), CT scan
results; 3) exposure history, including contact mode, number of residents in the household
and contact length; 4) symptoms and the date of symptom onset; 5) treatment received before
admission to the Fangcang Hospital. Raw data was compiled in an excel sheet, which was
imported to and analyzed using STATA V.14.1.
Statistical analysis
The primary outcome of this study is the LOS at the Fangcang Hospital, which was calculated
as the number of days that patients were hospitalized from admission to discharge.
We first conducted a descriptive analysis of patients’ demographic and clinical characteris-
tics, exposure history, common symptoms, treatment received and time course of the disease.
The distribution of continuous variables was assessed using the Shapiro-Wilk test. For nor-
mally distributed variables, means with standard deviation were calculated, while medians and
IQR were used to describe variables not normally distributed. Categorical variables were
described as frequency and percentage. To assess the differences in the demographic and
Fig 1. Flow chart of patients admitted to the Qiaokou Fangcang Hospital.
https://doi.org/10.1371/journal.pone.0240959.g001
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clinical characteristics between symptomatic and asymptomatic patients, we compared the
means and medians of continuous variables using the student’s t-test and Mann-Whitney U
test respectively. The differences in percentages of categorical variables between the two groups
were assessed using the chi-square test.
To identify factors influencing the LOS of patients at the Fangcang hospital, we conducted
multivariable linear regression analysis. The association between the outcome variable (LOS)
and each covariate was first assessed in univariable analysis. We performed a backward step-
wise selection to identify covariates to be included in the final multivariable linear regression
model. The selection was based on the Akaike Information Criterion (AIC): the added variable
would be included if the model gave a smaller AIC value compared with the one without the
added variable, suggesting that the model has better fitness with less complexity [24]. The
regression coefficient of each included covariate, the associated 95% confidence interval (CI)
and the two-sided p-value were reported. For all the statistical tests, a p-value less than 0.05
was considered statistically significant.
Ethical approval
Approval was taken from the Qiaokou Fangcang Hospital and the ethics committee of the
Shanxi Bethune Hospital (YXLL-KY-2020-001). Written informed consent was waived given
the context of a public health emergency.
Results
Patients’ characteristics and exposure history
In this study, we included a total of 58 patients who were hospitalized in the Qiaokou Fang-
cang Hospital and discharged between February 11th and March 1st, 2020. Among these
patients, 13 (22.4%) were identified as asymptomatic on admission. As shown in Table 1, the
median age of the patients was 55.5 years old (IQR = 20), and about 62.1% (N = 36) were
female. We also compared the demographic characteristics between the symptomatic and
asymptomatic patients. We observed that the asymptomatic group had an average age
(mean = 52, SD = 14) less than the symptomatic group (mean = 57, SD = 20) by 5 years and a
higher proportion of females (N = 10, 76.9%) than the symptomatic group (N = 26, 57.8).
However, the differences in age and gender between the two groups were not significant.
Apart from the 18 patients (31%) who did not recall their exposure history and 1 (1.7%)
who had visited the Huanan sea market, most of the patients (N = 32, 55.2%) were close con-
tacts of their confirmed family members, with fewer patients being exposed to confirmed
friends/colleagues (N = 3, 5.2%) or at mass gatherings (N = 4, 6.9%). The median number of
residents in a household was three (IQR = 2), and most of the patients (N = 30, 51.7%) had
contact with confirmed cases for longer than 24 hours. We also observed that 76.9% (N = 10)
of the asymptomatic patients had contact with confirmed family members, which is higher
than the proportion among symptomatic patients (N = 22, 48.9) by 28% (p = 0.056).
The clinical characteristics of the study participants are also presented in Table 1. Hyperten-
sion (N = 13, 22.4%) and diabetes (N = 6, 10.3%) were the most common comorbidities
reported by the patients. Only six participants (10.3%) reported a history of smoking. The
asymptomatic group had a lower proportion of patients with comorbidities (N = 3, 23.1%)
than the symptomatic group (N = 19, 42.2%), but the difference was not significant (p = 0.21).
While 37.9% (N = 22) and 39.7% (N = 23) of the patients had increased WBC level and lym-
phocyte level respectively, most of the patients had normal WBC (N = 35, 60.3%) and lympho-
cyte (N = 27, 46.5%) levels. No significant difference in WBC and lymphocyte levels between
symptomatic and asymptomatic groups was observed. At the time of hospital admission, most
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of the patients (N = 41, 70.7%) had an elevated CRP level. We observed that about 7.7 (N = 1)
of the asymptomatic patients had a CRP level over 10mg/L, which is significantly lower than
the proportion among symptomatic patients (N = 29, 64.4%) by 27.9% (p = 0.052). The CT
Table 1. Demographic and clinical characteristics of the patients and their exposure history.
Total (N = 58) Severity
Symptomatic (N = 45) Asymptomatic (N = 13) p-value
Demographic characteristics
Age, median (IQR) 55.5 (20) 57 (20) 52 (14) 0.28
Gender, N(%) 0.21
Male 22 (37.9) 19 (42.2) 3 (23.1) -
Female 36 (62.1) 26 (57.8) 10 (76.9) -
Exposure history
Contact mode, N (%) 0.056
Been to Huanan see market 1 (1.7) 1 (2.2) 0 (0) -
Contact with confirmed family member(s) 32 (55.2) 22 (48.9) 10 (76.9) -
Contact with confirmed friends or colleagues 3 (5.2) 1 (2.2) 2 (15.4) -
Involved in mass gathering 4 (6.9) 4 (8.9) 0 (0) -
Don’t know 18 (31) 17 (37.8) 1 (7.7) -
Number of people in the household, median (IQR) 3 (2) 3 (2) 3 (3) 0.33
Contact length, N (%) 0.088
Less than 1 hr 2 (3.5) 1 (2.2) 1 (7.7) -
Longer than 1 hr and less than 24 hrs 6 (10.3) 5 (11.1) 1 (7.7) -
Longer than 24 hours 30 (51.7) 20 (44.4) 10 (76.9) -
Don’t know 20 (34.5) 19 (42.2) 1 (7.7) -
Clinical characteristics
Any comorbidity, N (%) 22 (37.9) 19 (42.2) 3 (23.1) 0.21
Hypertension 13 (22.4) 11 (24.4) 2 (15.4) 0.5
Cardiovascular disease 3 (5.2) 3 (6.7) 0 (0) 0.34
Diabetes 6 (10.3) 6 (13.3) 0 (0) 0.16
Chronic liver disease 1 (1.7) 1 (2.22) 0 (0) 0.59
Smoking 6 (10.3) 5 (11.1) 1 (7.7) 0.72
WBC (x 109) 0.374
�4 and�10 35 (60.3) 29 (64.4) 6 (46.1)
<4 1 (1.72) 1 (2.2) 0 (0)
>10 22 (37.9) 15 (33.3) 7 (53.9)
Lymphocyte (%) 0.463
�20 and�40 27 (46.5) 22 (48.9) 5 (38.5)
<20 8 (13.8) 7 (15.5) 1 (7.7)
>40 23 (39.7) 16 (35.6) 7 (53.8)
CRP (mg/L) 0.052
�10 17 (29.3) 16 (35.6) 12 (92.3)
>10 41 (70.7) 29 (64.4) 1 (7.7)
Chest CT scan <0.001
None 10 (17.2) 3 (6.7) 7 (53.9) -
Unilateral pneumonia 12 (20.7) 9 (20.0) 3 (23.1) -
Bilateral pneumonia 36 (62.1) 33 (73.3) 3 (23.1) -
Outcome
Length of stay (LOS), mean (SD) 10.3 (4.9) 10.8 (5.2) 8.4 (3.4) 0.12
https://doi.org/10.1371/journal.pone.0240959.t001
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scan results showed that among symptomatic patients, 73.3% (N = 33) developed bilateral
pneumonia and only 3 (6.7%) patients had normal results. Three asymptomatic patients
(23.1%) developed unilateral pneumonia and three (23.1%) developed bilateral pneumonia,
even though they reported no perceivable symptoms at the time of hospital admission. The
proportion of bilateral pneumonia among the symptomatic group was significantly higher
than the proportion of the asymmetric group by 50.2% (p<0.001).
The mean time for hospitalization at the Fangcang hospital, which is the primary outcome
in our study, was 10.3 days (SD = 4.9). Even though asymptomatic patients (8.4 days,
SD = 3.4) had a shorter LOS than symptomatic patients (10.8 days, SD = 5.2) by 2.4 days, the
difference was not significant (p = 0.12).
Common symptoms
As reported by the symptomatic patients (N = 45), cough (N = 24, 41.4%) was the most com-
mon symptom at onset of illness, followed by fever (N = 23, 39.7) and fatigue (N = 21, 36.2%).
Less common symptoms were headache (N = 12, 20.7%), diarrhea (N = 6, 10.3%) and vomit
(N = 5, 8,6%) (Table 2).
Treatment received before admission and time course of COVID-19 among
study participants
As shown in Table 3, most patients (N = 41, 70.7%) had taken medications at the early stage of
infection before admitted to the Fangcang Hospital: almost half of the patients (N = 28, 48.3%)
received a combination of TCM and western medications (antiviral drugs or antibiotics); three
patients (5.2%) were prescribed with only western medications (antiviral drugs or antibiotics);
ten patients (17.2%) took TCM only. As reported by the patients, Oseltamivir and Arbidol
Table 2. Early symptoms among symptomatic patients.











Table 3. Treatment received before admission to the Qiaokou Fangcang Hospital and the time course of COVID-
19 among study participants.
Treatment received before admission to Fangcang hospital Number of patients (%)
None 17 (29.3)
TCM and antiviral or antibiotics treatments 28 (48.3)
Antiviral or antibiotics treatments 3 (5.2)
TCM only 10 (17.2)
Time course
Duration from symptom onset to admission to Fangcang (days), median (IQR) 13 (20)
Duration from symptom onset to discharge (days), median (IQR) 25 (20)
https://doi.org/10.1371/journal.pone.0240959.t003
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were the most commonly prescribed antiviral drugs. The antibiotics that the patients had
received included Moxifloxacin, Levofloxacin and Erythromycin.
For all the patients, the median durations from symptom onset to admission to the Fang-
cang Hospital and from symptom onset to discharge were 13 days (IQR = 20) and 25
(IQR = 20) days respectively.
Factors associated with length of hospitalization at the Fangcang Hospital
Results from the linear regression analysis in which we explored factors associated with the
length of hospital stay at the Qiaokou Fangcang Hospital are shown in Table 4. In the univari-
able analysis, we found that LOS was significantly associated with gender, having comorbidi-
ties (cardiovascular disease and diabetes), lymphocyte level, CT scan results, fever and
duration from symptom onset to hospital admission. Even though we observed a shorter LOS
in the groups of patients who were treated with only TCM (coefficient = -1.02, 95%CI -7.29 to
-5.25, p = 0.746) and only western medications (coefficient = -1.85, 95%CI -5.84 to 2.14,
p = 0.356) than in the non-treatment group, the differences were not significant.
In the multiple variable linear regression analysis, we included the following variables in
our final model: diabetes, durations from symptom onset to admission, fever and chest CT
scan results. Our analysis showed that longer LOS was significantly associated with having
fever on admission, shorter duration from symptom onset to admission, and having bilateral
pneumonia after adjusting for other covariates. We found strong evidence to indicate that
patients having fever before admission had significantly longer LOS than those without fever
by 3.5 days (95%CI 1.39 to 5.63, p = 0.002) and that patients having bilateral pneumonia were
hospitalized 3.4 days (95%CI 0.49 to 6.25, p = 0.023) longer than those with normal CT scan
results. We also observed that patients who experienced shorter duration from symptom onset
to admission had significantly longer LOS. Even though the evidence was strong (p<0.001),
the magnitude of this association was very small (coefficient = -0.21, 95%CI -0.30 to -0.12).
Furthermore, we found weak evidence showing an association between LOS and diabetes after
adjusting for other variables. Patients with diabetes were hospitalized 3.2 days longer than
those without diabetes (95%CI -0.2 to 6.56, p = 0.065).
Discussion
In this retrospective cohort study of non-severe COVID-19 patients admitted to a Fangcang
hospital, we found that longer hospitalization is associated with having fever, bilateral pneu-
monia, shorter duration from symptom onset to admission and diabetes. However, there is no
significant difference in the LOS at Fangcang hospitals between asymptomatic and symptom-
atic patients and between patients who received medications and those without treatment
before hospital admission.
According to a systematic review of COVID-19 length of hospital stay, the median LOS at
general hospitals (non-ICU) in China is 14 days (IQR:10–19) [20], which is four days longer
than the median in our study. This can be explained by the different admission criteria
between Fangcang hospitals and general hospitals outside of Wuhan. In Wuhan, patients were
screened for disease severity and only non-severe patients (asymptomatic patients and those
with minor and moderate symptoms) were referred to Fangcang hospitals. This patient triage
scheme was only implemented inWuhan to accommodate the rapid surge of cases in January
and February 2020, but not in the other cities because the outbreak was soon contained after
the lockdown of Wuhan. As a result, patients outside of Wuhan were admitted to and hospital-
ized in local general hospitals regardless of disease severity. In many existing studies conducted
outside of Wuhan, both non-severe and severe patients who were hospitalized in tertiary
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Table 4. Factors associated with LOS.
Univariable analysis Multivariable analysis
Coefficient (95% CI) p-value Coefficient (95% CI) p-value
Asymptomatic
No Reference - - -
Yes -2.44 (-5.52, 0.64) 0.119 - -
Age 0.08 (-0.01, 0.17) 0.096 - -
Gender
Male Reference - - -
Female -2.63 (-5.24, -0.02) 0.048 - -
Any comorbidity 1.75 (-0.91, 4.42) 0.193 - -
Hypertension 2.02 (-1.08, 5.13) 0.197 - -
Heart disease -6.3 (-11.95, -0.58) 0.031 - -
Diabetes 5.64 (1.60, 9.68) 0.007 3.18 (-0.20, 6.56) 0.065
Chronic liver disease -1.29 (-11.38, 8.78) 0.797 - -
Smoking 1.92 (-2.36, 6.20) 0.372 - -
Number of people in the household, median 0.56 (-0.18, 1.30) 0.138 - -
Contact length
Less than 1 hr Reference - - -
Longer than 1 hr and less than 24 hrs 4.5 (-3.73, 12.73) 0.278 - -
Longer than 24 hours 3.27 (-4.09, 10.63) 0.378 - -
Don’t know 3.25 (-4.23, 10.73) 0.387 - -
WBC (x 109)
�4 and�10 Reference - - -
<4 -6.31 (-16.40, 3.77) 0.215 - -
>10 0.19 (-2.52, 2.89) 0.891 - -
Lymphocyte (%)
�20 and�40 Reference - - -
<20 4.8 (0.95, 8.7) 0.015 - -
>40 1.36 (-1.35,4.07) 0.319 - -
CRP (mg/L)
�10 Reference - - -
>10 -1.61 (-4.46, 1.25) 0.254 - -
Chest CT scan
None Reference - Reference -
Unilateral pneumonia -0.3 (-4.22, 3.62) 0.879 -0.28 (-3.48, 2.92) 0.861
Bilateral pneumonia 4.09 (0.82, 7.36) 0.015 3.37 (0.49, 6.25) 0.023
Cough 1.16 (-1.48, 3.81) 0.382 - -
Phlegm 1.73 (-1.39, 4.84) 0.272 - -
Fatigue 1.88 (-0.80, 4.57) 0.166 - -
Muscle ache -0.95 (-4.09, 2.19) 0.547 - -
Headache -0.45 (-3.69, 2.79) 0.780 - -
Heard to breathe 0.83 (-2.31, 3.98) 0.597 - -
Fever 3.22 (0.68, 5.76) 0.014 3.51 (1.39, 5.63) 0.002
Diarrhea 1.55 (-2.73, 5.84) 0.472 - -
Vomit 0.79 (-3.88, 5.47) 0.735 - -
Interval between symptom onset to admission to Fangcang (days) -0.16 (-0.27, -0.05) 0.005 -0.21 (-0.30, -0.12) <0.001
Treatment received before Fangcang
None Reference - - -
(Continued)
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hospitals were included in the study populations [15, 22, 25, 26]. However, studies in the set-
ting of Fangcang hospitals were scarce. To our knowledge, only one study focused on the clini-
cal characteristics of patients stayed in a Fangcang hospital in Wuhan; however, it did not
report LOS as an outcome indicator, thus a comparison was not possible [7].
We found that the duration of hospital stay is associated with two signs of the inflammatory
response—fever and bilateral pneumonia on chest CT scan–among non-severe COVID-19
patients. Fever has been used widely as an indicator for screening people suspected of COVID-
19 and assessing disease severity in the COVID-19 diagnostic and treatment guidelines in
China [2, 27–29]. It is the most reported symptom in COVID-19 patients and found to be
more common in severe patients, as a meta-analysis found that the incidences of fever in the
total study population and in the severe patients were 89.1% and 93.5% respectively [30].
Despite that fever was less common in our study than in the other studies due to the admission
criteria of Fangcang hospitals that excluded severe COVID-19 cases, our findings suggest that
patients who reported having fever at the early stage of infection require longer hospitalization,
which is consistent with previous studies [21, 22]. Similarly, as a result of pulmonary inflam-
mation caused by viral infection, radiological changes in the lungs is common among
COVID-19 patients. As reported in a meta-analysis of 43 studies, 73% of patients developed
bilateral pneumonia [29]. We observed a similar prevalence of bilateral pneumonia and con-
firmed with a previous study that bilateral pneumonia on CT scan is associated with longer
duration of hospital stay [21].
Asymptomatic patients have less severe clinical manifestations than symptomatic patients,
as the prevalence of bilateral pneumonia was significantly lower than the prevalence in the
symptomatic group. However, we observed no significant difference in LOS between the two
groups. This could be explained by that asymptomatic and symptomatic patients have similar
viral loads, as reported in a previous study [31]. It is also possible that some patients were in
presymptomatic phase when they were confirmed with COVID-19. Additionally, despite that
a study of 24 asymptomatic cases suggest that young patients less than 15 years old are more
likely to be asymptomatic [32], we did not find any significant differences in demographic
characteristics or the prevalence of comorbidities between asymptomatic and symptomatic
patients due to older age group of our study participants and small sample size.
Diabetes is the second most prevalent comorbidity among COVID-19 patients [33]. The
prevalence of diabetes in our study is similar to its prevalence among other COVID-19 study
populations (9.7%) and the total population (10.9%) in China [33]. Although it is still incon-
clusive whether diabetes is a risk factor for severe COVID-19 [33, 34], we found weak evidence
suggesting that diabetes is associated with longer hospital stay among non-severe COVID-19
patients. One explanation could be that diabetes may impair the functions of macrophage and
lymphocyte and adversely affect T-cell growth and production of interferon γ, thus leading to
suppressed immunological function [35, 36]. It is also possible that viral infection, such as
influenza, may lead to fluctuations in blood glucose level, which may exacerbate the complica-
tions of diabetes and prolong the recovery process [37–39].
Table 4. (Continued)
Univariable analysis Multivariable analysis
Coefficient (95% CI) p-value Coefficient (95% CI) p-value
TCM and antiviral or antibiotics treatments 0.61 (-2.47, 3.69) 0.692 - -
Antiviral or antibiotics treatments -1.02 (-7.29, 5.25) 0.746 - -
TCM only -1.85 (-5.84, 2.14) 0.356 - -
https://doi.org/10.1371/journal.pone.0240959.t004
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Additionally, we observed that pre-existing cardiovascular comorbidities, such as hyperten-
sion and heart diseases, were prevalent among our participants. Although we did not observe
significant associations between cardiovascular diseases and LOS, previous studies have shown
that they are risk factors for COVID-19 infection and poor prognosis [40, 41]. One explanation
could be that the virus is able to bind to the angiotensin-converting enzyme 2 (ACE2), thus
affecting the ACE2 signaling pathways and leading to acute cardiac injury [40]. Experts also
suspect that the acute systemic inflammatory response caused by the uncontrolled release of
pro-inflammatory cytokines may affect the cardiovascular system [40], as pro-inflammatory
cytokines storm was observed among severe COVID-19 patients in several studies [27, 42, 43].
Consistent with other studies in China, antibiotics and antiviral medications are commonly
prescribed to COVID-19 patients [26, 44, 45]. Although no proven effective antiviral treatment
specifically for COVID-19 exists, antiviral medications such as Arbidol and Lopinavir are rec-
ommended in the early editions of COVID-19 diagnostic and treatment guidelines in China
and drugs to relieve symptoms and inflammation responses are often prescribed by doctors at
fever clinics [2]. Additionally, TCM has been used for treating viral infections, such as H1N1
and MERS, and recommended in the COVID-19 diagnostic and treatment guidelines in
China [2, 46]. Although we did not find a significant difference in hospitalization duration
between patients who received medications and those without pharmaceutical treatment, a
number of medications are shown to be effective as supportive treatment of COVID-19. For
example, early use of “Lianhuaqingwen” capsules–a Chinese proprietary medicine commonly
used for treating cold and flu—has significantly improved the recovery of symptoms [47].
However, to reach a consensus on effective therapies, more clinical data on pharmaceutical
treatment for COVID-19 are urgently needed.
Strengths and limitations
Our study provides evidence for predicting hospital bed demand in a novel public health
response scenario by examining the length of hospitalization—an important but underre-
ported indicator—and its associated factors among non-severe COVID-19 patients hospital-
ized in Fangcang hospitals. The findings are useful for decision-makers to prepare for ramping
up the health system capacity and planning for resource allocation. In this study, we also give
more insights on patient management within Fangcang hospitals and the characteristics of
patients in these hospitals. Therefore, our study is informative for frontline healthcare provid-
ers in countries which are planning to adopt the “Fangcang” model. Finally, we highlight the
influence of being asymptomatic and diabetic on LOS, which can be useful for clinicians when
making treatment plans for those groups of COVID-19 patients.
Our study has the following limitations. First, this is a single-centered study with a relatively
small sample size, which may limit our interpretation of the analysis results. Second, informa-
tion on medical history, treatment received before admission to Fangfang hospitals and the date
of diagnosis and symptom onset was reported by the patients and susceptible to recall bias.
However, because of the retrospective cohort study design, errors in reporting are likely to be
non-differential across the study participants. Finally, because a standard treatment was pro-
vided to all the patients during their hospitalization in Fangcang hospitals, we only included
treatment received before admission to Fangcang hospitals as a variable in the analysis.
Conclusion
In this retrospective cohort study of non-severe COVID-19 patients who were staying in a
Fangcang hospital, we found that longer duration of hospitalization is associated with having
fever, bilateral pneumonia on CT scan, shorter duration from symptom onset to admission
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and diabetes. However, being asymptomatic and using supportive medications at the early
stage of infection do not have significant influences on the length of hospital stay. Our study
provides evidence for predicting hospital bed demand in a novel public health response sce-
nario where emergency hospitals are deployed to meet the needs of a large number of non-
severe patients and may help decision-makers in the early preparation for the second wave of
COVID-19 cases.
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